32 results on '"Takano, Natsuki"'
Search Results
2. Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study
3. Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma: A Case Report
4. Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
5. Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
6. Carboplatin plus nanoparticle albumin‑bound paclitaxel for the treatment of thymic carcinoma
7. A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
8. Exosome‐derived miR ‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition inEGFRmutant non‐small cell lung cancer cells
9. A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and Pemetrexed
10. Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
11. Abstract 3068: The glycoprotein inhibitors overcome the resistance of the topoisomerase inhibitors in small cell lung cancer
12. Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
13. Examination of a technique to present the feeling of swimming endlessly underwater by the mechanism to pull back the body and the visual stimulus
14. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study
15. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
16. Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
17. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
18. The role of polo-like kinase1 inhibition in Small Cell Lung Carcinomas
19. A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
20. Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
21. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib
22. Correlation of low CT attenuation and necrotic features of tumor in contrast-enhanced CT with nivolumab response.
23. Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo).
24. Detection of EGFR mutations in NSCLC patients in clinical practice: Comparison between cobas and Scorpion ARMS method.
25. The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice.
26. Preexistence of CT findings with usual interstitial pneumonia (UIP) pattern correlates to radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients receiving chemoradiotherapy (CRT).
27. The reasons why re-biopsies were not performed after failure with EGFR-TKI.
28. Clinical and radiological features of advanced RET-rearranged lung cancer.
29. EGFR mutation type and efficacy of afatinib in patients who previously treated with EGFR-TKI.
30. Feasibility of EBUS-TBNA specimens for PD-L1 expression test in lung cancer.
31. Current situation of re-biopsy in non small-cell lung cancer treated with EGFR-TKI.
32. Crizotinib-induced severe ulcerative esophagitis three years after chemoradiotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.